CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Sees Significant Decrease in Short Interest

CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 49,357 shares, a decrease of 97.5% from the December 15th total of 1,939,991 shares. Based on an average daily trading volume, of 27,586,017 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 27,586,017 shares, the short-interest ratio is currently 0.0 days.

CNBX Pharmaceuticals Price Performance

OTCMKTS:CNBX traded down $0.00 on Monday, reaching $0.00. 47,848,193 shares of the stock traded hands, compared to its average volume of 27,006,211. CNBX Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.02.

CNBX Pharmaceuticals Company Profile

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.